title: Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice.
abstract: OBJECTIVE
  Evaluate the association between the multi-biomarker disease activity (MBDA) score and radiographic progression in patients with rheumatoid arthritis (RA) treated with tumor necrosis factor (TNF)-α inhibitors.
  
  
  METHODS
  Change (Δ) in modified total Sharp score (mTSS) over 52 weeks and disease activity scores were examined retrospectively by Spearman's rank correlation coefficient in patients (N = 83) with RA initiating TNF-inhibitor treatment. Relative risk (RR) of ΔmTSS >0.5 for low MBDA score and 28-joint count disease activity score (DAS28) categories and associations between ΔmTSS and MBDA score categories conditional on DAS28 categories were assessed.
  
  
  RESULTS
  At 52 weeks, 34% of patients had ΔmTSS >0.5 and 12% had ΔmTSS >3. Strongest correlations were observed between ΔmTSS and MBDA score (r = 0.47) or DAS28 (r = 0.42) at Week 24 and for area under the curve at Week 52 (MBDA score: r = 0.44, DAS28: r = 0.41), all p < 0.001. At Week 24, RR of ΔmTSS >0.5 for moderate/high MBDA score (≥30) or DAS28 (>3.2) were 6.6 (p < 0.001) and 2.7 (p = 0.005), respectively. Low DAS28 had greater risk of ΔmTSS >0.5 at 52 weeks when MBDA score was ≥30 (p < 0.05).
  
  
  CONCLUSIONS
  Higher MBDA score or DAS28 at Week 24 was associated with greater radiographic progression over 52 weeks of TNF-inhibitor treatment. MBDA score improved risk discrimination for radiographic progression within DAS28 categories.
authors.affiliation: a The First Department of Internal Medicine, School of Medicine , University of Occupational and Environmental Health, Japan , Kitakyushu , Japan and.
authors.forename: Shintaro
authors.initials: S
authors.lastname: Hirata
authors.affiliation: b Crescendo Bioscience Inc. , South San Francisco , CA , USA.
authors.forename: Wanying
authors.initials: W
authors.lastname: Li
authors.affiliation: a The First Department of Internal Medicine, School of Medicine , University of Occupational and Environmental Health, Japan , Kitakyushu , Japan and.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kubo
authors.affiliation: a The First Department of Internal Medicine, School of Medicine , University of Occupational and Environmental Health, Japan , Kitakyushu , Japan and.
authors.forename: Shunsuke
authors.initials: S
authors.lastname: Fukuyo
authors.affiliation: a The First Department of Internal Medicine, School of Medicine , University of Occupational and Environmental Health, Japan , Kitakyushu , Japan and.
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Mizuno
authors.affiliation: a The First Department of Internal Medicine, School of Medicine , University of Occupational and Environmental Health, Japan , Kitakyushu , Japan and.
authors.forename: Kentaro
authors.initials: K
authors.lastname: Hanami
authors.affiliation: a The First Department of Internal Medicine, School of Medicine , University of Occupational and Environmental Health, Japan , Kitakyushu , Japan and.
authors.forename: Norifumi
authors.initials: N
authors.lastname: Sawamukai
authors.affiliation: a The First Department of Internal Medicine, School of Medicine , University of Occupational and Environmental Health, Japan , Kitakyushu , Japan and.
authors.forename: Kunihiro
authors.initials: K
authors.lastname: Yamaoka
authors.affiliation: a The First Department of Internal Medicine, School of Medicine , University of Occupational and Environmental Health, Japan , Kitakyushu , Japan and.
authors.forename: Kazuyoshi
authors.initials: K
authors.lastname: Saito
authors.affiliation: b Crescendo Bioscience Inc. , South San Francisco , CA , USA.
authors.forename: Nadine A
authors.initials: NA
authors.lastname: Defranoux
authors.affiliation: a The First Department of Internal Medicine, School of Medicine , University of Occupational and Environmental Health, Japan , Kitakyushu , Japan and.
authors.forename: Yoshiya
authors.initials: Y
authors.lastname: Tanaka
mesh_terms: D000068879:Adalimumab / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000000981:diagnostic imaging / Q000188:drug therapy*; D015415:Biomarkers; D018450:Disease Progression; D000068800:Etanercept / Q000627:therapeutic use; D005260:Female; D033023:Foot Joints / Q000000981:diagnostic imaging; D050823:Hand Joints / Q000000981:diagnostic imaging; D006801:Humans; D000069285:Infliximab / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D018501:Antirheumatic Agents; D015415:Biomarkers; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab; D000068800:Etanercept
keywords: Biomarkers; MBDA score; Radiographic progression; Rheumatoid arthritis; TNF inhibitor